A quick note from Behind the Markets
The “smart money” loves to pretend it can see around corners.
But markets don’t move on what’s true. They move on what becomes unavoidable. And right now, three things are becoming unavoidable: energy risk is back, Washington is turning the AI supply chain into leverage, and Big Pharma is writing checks again.
That’s where independent investors can win.
Not by guessing the next Fed whisper. By spotting regime shifts before Wall Street consensus updates its slide deck.
1) Oil Isn’t a Trade. It’s a Threat Assessment (And It’s Back on the Board)
Wall Street wants you to believe oil is “just another commodity.” Something you trade on charts.
In reality, oil is a geopolitical instrument — and a direct tax on the economy.
Late March gave us a reminder. Brent pushed above $111 and WTI headed toward $100 after fresh disruption fears tied to the Strait of Hormuz, including reports that two Chinese vessels were blocked from transiting the route. The bigger point is the same one markets relearn every time this chokepoint flashes red: energy shocks do not stay inside the energy sector.
Here’s the investing angle that matters for April: the first hit isn’t at the pump. It’s inside earnings reports. Freight. Chemicals. Packaging. Airlines. Anything with thin margins.
That’s why “oil up” is rarely just “energy stocks up.” It’s “every business model gets stress-tested.”
Bottom line: In April, the question isn’t “will oil pull back?” The question is: which companies can’t survive another quarter of higher input costs? That’s where surprises happen.
Company: ConocoPhillips (SYM: COP)
Large-scale crude leverage.
ConocoPhillips is currently trading around $128. It is one of the world’s largest independent E&P companies, and management’s 2026 production guidance calls for 2.33 to 2.36 MMBOED. If you want a cleaner way to express “energy risk stays live,” this is one of the more direct ways to do it.
Banyan Hill Publishing
The REAL Reason Trump Is Invading Iran
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.
Click here to find out what it is.
If you have even a single dollar invested in the U.S. stock market, this is going to directly impact you.
2) The Next AI Bottleneck Isn’t Compute. It’s Politics (Export Controls Are the New Supply Chain)
Investors are still stuck in 2023 thinking AI is purely a capex story: GPUs in, profits out.
But the next phase of AI is political. And policy risk is becoming a first-class variable in AI valuations.
Reuters reported earlier in March that U.S. officials were debating a new export-control framework that could tighten licensing for AI chip deployments — with draft thresholds that went all the way down to sub-1,000 chip installations potentially needing a license, tougher requirements at higher volumes, and exports potentially tied to foreign investment in U.S. AI data centers or security assurances. That specific draft was later withdrawn, but Commerce has separately said it is formalizing a “secure exports of the American tech stack” approach and has moved ahead with the American AI Exports Program.
Translation: the AI “arms race” is getting gated.
And gating changes everything:
It changes who can build at scale.
It changes the timeline for international demand.
It raises the value of domestic data center buildouts.
It pressures the “sell shovels globally” thesis.
This doesn’t kill AI. It reshapes the winners.
Bottom line: If export controls stay in motion, AI becomes less of a global free-for-all — and more of a U.S.-centric infrastructure build. Watch who benefits when supply can’t freely chase demand.
Company: Vertiv Holdings (SYM: VRT)
Power and cooling for the AI buildout.
Vertiv is currently trading around $263. The company describes itself as a leader in critical digital infrastructure for data centers, and in March announced a collaboration with Generate Capital aimed at accelerating data center capacity deployment in power-constrained markets. If policy keeps steering AI spend toward domestic infrastructure, that is the kind of second-order winner that matters.
3) Biotech M&A Is Heating Up — Which Means Wall Street’s “Risk-Off” Narrative Is Lying
When Big Pharma is scared, it hoards cash and buys back stock.
When Big Pharma sees opportunity (and looming pipeline holes), it buys science.
Late March brought multiple big biotech deals, including Biogen’s roughly $5.6 billion agreement for Apellis and Eli Lilly’s deal for Centessa valued up to $7.8 billion, both announced on March 31. That’s not theory. That’s cash on the table.
You don’t need to own those exact targets to make money from this.
M&A waves do two important things for retail investors:
They re-rate entire subsectors (because acquirers reveal what they’re willing to pay for quality assets).
They change the financing climate for earlier-stage names (because the exit market looks real again).
The trick is not chasing the headline premium after the gap-up. The trick is identifying the “next rung down” — the under-covered companies with real assets, clean balance sheets, and catalysts inside a 6–12 month window.
Bottom line: A real M&A tape is bullish information. Not for the indexes — for the right small/mid-cap biotechs with de-risked programs and impatient shareholders.
Company: Ocular Therapeutix (SYM: OCUL)
Cash-backed retina pipeline with live catalysts.
Ocular Therapeutix is currently trading around $8.60. The company ended 2025 with $737.1 million in cash, expects runway into 2028, and has a Phase 3 retina program plus HELIOS-3 underway. That does not make it a takeout prediction. It makes it the kind of asset-rich small/mid-cap biotech that can rerate fast when buyers start putting real prices on real pipelines again.
Wyatt Investment Research
Secretary of Defense: This is the truth about SpaceX
Secretary of War Pete Hegseth just confessed...
That SpaceX is "strategically indispensable" to U.S. national security.
The company went from just another "crazy idea" from Musk to being worth more than Coca-Cola.
That's why I'm claiming my stake right now - months before the IPO.
Here's how you can join me (email required).
4) Mark Your Calendar: Inflation Data Is Quiet… Until It Isn’t
Markets don’t wait for CPI day to care about CPI.
They front-run it.
The Bureau of Labor Statistics schedule shows the March 2026 CPI report is due April 10, 2026 at 8:30 AM Eastern. The latest BLS release showed CPI up 2.4% year over year in February, which is why another energy-driven upside surprise would matter.
That matters because April is when “hope” meets “math.”
If inflation comes in sticky while energy stays elevated, the market’s favorite bedtime story — easy cuts, easy multiples, easy rallies — gets tougher.
If inflation cools, risk assets get a permission slip.
Either way, the setup is the same: volatility tends to compress before the number, then break one way or the other after.
Bottom line: Don’t drift into CPI week with blind exposure. If you’re going to swing, swing with a plan.
Company: CME Group (SYM: CME)
Macro-volatility toll collector.
CME Group is currently trading around $296. The company describes itself as the world’s leading derivatives marketplace, with products used for risk management across major asset classes. Around CPI week, that means you’re not married to one inflation outcome as much as you’re leaning into the odds that traders pay to hedge the move.
Before You Go
Here’s the contrarian question for April 2:
If Washington is turning AI chips into geopolitical leverage… and oil chokepoints are acting like on/off switches… why are people still investing as if 2019 rules apply?
The market’s not broken.
It’s being re-priced for a different world.
Found this helpful? Share it with others.
Written by Behind the Markets